ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial
Abstract Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-03-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-00874-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849392452161503232 |
|---|---|
| author | Thomas J. Herzog Thomas C. Krivak Stephen Bush John P. Diaz Scott Lentz Navya Nair Nadim Bou Zgheib Camille Gunderson-Jackson Abhijit Barve Krista L. Denning Seth T. Lirette Candace M. Howard Jagan Valluri Pier Paolo Claudio |
| author_facet | Thomas J. Herzog Thomas C. Krivak Stephen Bush John P. Diaz Scott Lentz Navya Nair Nadim Bou Zgheib Camille Gunderson-Jackson Abhijit Barve Krista L. Denning Seth T. Lirette Candace M. Howard Jagan Valluri Pier Paolo Claudio |
| author_sort | Thomas J. Herzog |
| collection | DOAJ |
| description | Abstract Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate (ORR) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI95 39% - 73%), compared to 5% (CI95 0% - 11%) for those treated with physician’s choice chemotherapy (p <0.0001). Secondary endpoints of duration of response (DOR) and progression-free survival (PFS) of subjects treated with chemotherapies guided by the ChemoID assay versus physician’s choice chemotherapy were a median of 8 months vs. 5.5 months (p <0.0001), and 11.0 months (CI95 8.0– NA) vs 3.0 months (CI95 2.0– 3.5) with 27% of hazard ratio (CI95, 0.15–0.49; p <0.001), respectively. |
| format | Article |
| id | doaj-art-3e8c0567a1ec4faa9f58d9a8c85c1ded |
| institution | Kabale University |
| issn | 2397-768X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Precision Oncology |
| spelling | doaj-art-3e8c0567a1ec4faa9f58d9a8c85c1ded2025-08-20T03:40:46ZengNature Portfolionpj Precision Oncology2397-768X2025-03-019112310.1038/s41698-025-00874-0ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trialThomas J. Herzog0Thomas C. Krivak1Stephen Bush2John P. Diaz3Scott Lentz4Navya Nair5Nadim Bou Zgheib6Camille Gunderson-Jackson7Abhijit Barve8Krista L. Denning9Seth T. Lirette10Candace M. Howard11Jagan Valluri12Pier Paolo Claudio13Department of Obstetrics and Gynecology, University of Cincinnati Cancer CenterDivision of Gynecologic Oncology, Allegheny Health Network Cancer InstituteDepartment of Obstetrics and Gynecology, Charleston Area Medical Center Vandalia HealthGynecologic Oncology, Baptist Health South Florida, Miami Cancer InstituteGynecology Oncology Department, Kaiser Permanente Los Angeles Medical CenterDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, Louisiana State UniversityEdwards Comprehensive Cancer Center, Joan C. Edwards School of Medicine, Marshall UniversityDepartment of Obstetrics and Gynecology, Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences CenterClinical Development & Medical Affairs, Viatris IncDepartment of Pathology, Joan C. Edwards School of Medicine, Marshall UniversityDepartment of Data Science, University of Mississippi Medical Center, Translational Research CenterDepartment of Radiology, University of Mississippi Medical CenterCordgenics, LLCCordgenics, LLCAbstract Patients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs). The NCT03949283 randomized clinical trial enrolled patients with recurrent PROC to receive ChemoID-guided chemotherapy or the best physician-choice regimen selected from the same list of thirteen mono or combination chemotherapies. The primary outcome was objective response rate (ORR) assessed on CT scans using the RECIST 1.1 criteria at 6 months follow-up. Subjects treated with the ChemoID assay had an ORR of 55% (CI95 39% - 73%), compared to 5% (CI95 0% - 11%) for those treated with physician’s choice chemotherapy (p <0.0001). Secondary endpoints of duration of response (DOR) and progression-free survival (PFS) of subjects treated with chemotherapies guided by the ChemoID assay versus physician’s choice chemotherapy were a median of 8 months vs. 5.5 months (p <0.0001), and 11.0 months (CI95 8.0– NA) vs 3.0 months (CI95 2.0– 3.5) with 27% of hazard ratio (CI95, 0.15–0.49; p <0.001), respectively.https://doi.org/10.1038/s41698-025-00874-0 |
| spellingShingle | Thomas J. Herzog Thomas C. Krivak Stephen Bush John P. Diaz Scott Lentz Navya Nair Nadim Bou Zgheib Camille Gunderson-Jackson Abhijit Barve Krista L. Denning Seth T. Lirette Candace M. Howard Jagan Valluri Pier Paolo Claudio ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial npj Precision Oncology |
| title | ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial |
| title_full | ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial |
| title_fullStr | ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial |
| title_full_unstemmed | ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial |
| title_short | ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial |
| title_sort | chemoid guided therapy improves objective response rate in recurrent platinum resistant ovarian cancer randomized clinical trial |
| url | https://doi.org/10.1038/s41698-025-00874-0 |
| work_keys_str_mv | AT thomasjherzog chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT thomasckrivak chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT stephenbush chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT johnpdiaz chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT scottlentz chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT navyanair chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT nadimbouzgheib chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT camillegundersonjackson chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT abhijitbarve chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT kristaldenning chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT sethtlirette chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT candacemhoward chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT jaganvalluri chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial AT pierpaoloclaudio chemoidguidedtherapyimprovesobjectiveresponserateinrecurrentplatinumresistantovariancancerrandomizedclinicaltrial |